Cite
APA Citation
Li, T., LoRusso, P., Maitland, M., Ou, S., Bahceci, E., Ball, H., Park, J., Yuen, G., & Tolcher, A. (2016). first-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. Journal of hematology & oncology, 9(1), 1–9. http://access.bl.uk/ark:/81055/vdc_100080439678.0x000063